Fatal case of bilateral internal jugular vein thrombosis following IVIg infusion in an adolescent girl treated for ITP

American Journal of Hematology

Volumn 83, Issue 4, 2008, Pages 323-325

  Tam, Pui Ying Iroh ^a,b   Richardson, Matthew ^a   Grewal, SatKiran ^a  

^a Baystate Children's Hospital   (United States)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DEXAMETHASONE; ESTROGEN; ETHINYLESTRADIOL PLUS NORETHISTERONE ACETATE; GADOLINIUM; GESTAGEN; HEPARIN; IMMUNOGLOBULIN; IRON; MANNITOL; PARACETAMOL;

ADOLESCENT; ANAMNESIS; ARTICLE; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; HEADACHE; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; INTERNAL JUGULAR VEIN; IRON DEFICIENCY ANEMIA; LABORATORY TEST; MAGNETIC RESONANCE ANGIOGRAPHY; PRIORITY JOURNAL; THROMBECTOMY; THROMBOCYTE COUNT; UTERUS BLEEDING; VEIN THROMBOSIS;

ADOLESCENT; ANEMIA, IRON-DEFICIENCY; ANTICOAGULANTS; BRAIN EDEMA; COMBINED MODALITY THERAPY; DEXAMETHASONE; ETHINYL ESTRADIOL; FATAL OUTCOME; FEMALE; HEPARIN; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; INFUSIONS, INTRAVENOUS; JUGULAR VEINS; MANNITOL; METRORRHAGIA; NORETHINDRONE; OBESITY; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; THROMBECTOMY; THROMBOLYTIC THERAPY; VENOUS THROMBOSIS;

EID: 41449094100     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.21107     Document Type: Article

References (14)

1. Eibl MM. Intravenous immunoglobulins in neurological disorders: Safety issues. Neurol SCi 2003;24 (Suppl 4): S222-S226.
2. Paran D, Herishanu Y, Elkayam O, et al. Venous and arterial thrombosis following administration of intravenous immunoglobulins. Blood Coagul Fibrinolysis 2005;16:313-318.
3. Vucic S, Chong PS, Dawson KT, et al. Thromboembolic complications of intravenous immunoglobulin treatment. Eur Neurol 2004;52:141-144.
4. Schiavotto C, Ruggeri M, Rodeghiero F. Adverse reactions after high-dose intravenous immunoglobulin: Incidence in 83 patients treated for idiopathic thrombocytopenic purpura (ITP) and review of the literature. Haematologica 1993;78(6, Suppl 2):35-40.
5. van Ommen CH, Peters M. Venous thromboembolic disease in childhood. Semin Thromb Hemost 2003;29:391-404. Review.
6. Chen C, Danekas LH, Ratko TA, et al. A multicenter drug use surveillance of intravenous immunoglobulin utilization in US academic health centers. Ann Pharmacother 2000;34:295-299.
7. Evangelou N, Litttlewood T, Anslow P, Chapel H. Transverse sinus thrombosis and IVIg treatment: A case report and discussion of risk-benefit assessment for immunoglobulin treatment. J Clin Pathol 2003;56:308-309.
8. Andrew M, David M, Adams M, et al. Venous thromboembolic complications (VTE) in children: First analyses of the Canadian Registry of VTE. Blood 1994;83:1251-1257.
9. Martinelli I. von Willebrand factor and factor VIII as risk factors for arterial and venous thrombosis. Semin Hematol 2005;42:49-55.
10. Stolz E, Valdueza JM, Grebe M, et al. Anemia as a risk factor for cerebral venous thrombosis? An old hypothesis revisited: Results of a prospective study. J Neurol 2007;254:729-734.
11. Reinhart WH, Berchtold PE. Effect of high-dose intravenous immunoglobulin therapy on blood rheology. Lancet 1992;339:662-664.
12. Koster T, Blann AD, Briet E, et al. Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep-vein thrombosis. Lancet 1995;345:152-155.
13. Sebire G, Tabarki B, Saunders DE, et al. Cerebral venous sinus thrombosis in children: Risk factors, presentation, diagnosis and outcome. Brain 2005;128 (Part 3):477-489.
14. Anderson D, Ali K, Blanchette V, et al. Guidelines on the use of intravenous immune globulin for hematologic conditions. Transfus Med Rev. 2007;21(2, Suppl 1):S9-S56.